PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Clin Pathol. 1999 July; 52(7): 535–537.
PMCID: PMC501499

Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

Abstract

The separation of mesothelial hyperplasia from early malignant mesothelioma remains one of the most difficult problems in histopathology. Inconclusive cases are termed "atypical mesothelial hyperplasia" and treated expectantly. A 49 year old male pipeline engineer was diagnosed as having atypical mesothelial hyperplasia in appendiceal serosa by the US-Canadian Mesothelioma Panel. Eight years later, he developed overtly malignant peritoneal and pleural mesothelioma. In hindsight, histological similarities between the diffuse malignant mesothelioma and the atypical mesothelial proliferation suggested malignancy from the outset. The most important of these features were the degree of mesothelial proliferation, micronodularity, architectural complexity, superficial invasion, uniform mild cytological atypia, and the absence of a clinical cause for a benign mesothelial proliferation. Ancillary investigations including immunohistochemistry were of no benefit in determining whether the atypical mesothelial hyperplasia was benign or malignant. Careful histological examination remains the mainstay of the diagnosis of early mesothelioma.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (822K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • McCaughey WT, Al-Jabi M. Differentiation of serosal hyperplasia and neoplasia in biopsies. Pathol Annu. 1986;21(Pt 1):271–293. [PubMed]
  • Burmer GC, Rabinovitch PS, Kulander BG, Rusch V, McNutt MA. Flow cytometric analysis of malignant pleural mesotheliomas. Hum Pathol. 1989 Aug;20(8):777–783. [PubMed]
  • Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, van Marck E. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992 Dec;168(4):371–375. [PubMed]
  • Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):377–381. [PubMed]
  • Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. p53 expression is common in malignant mesothelioma. Histopathology. 1992 Oct;21(4):331–334. [PubMed]
  • Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol. 1994 May;25(5):443–448. [PubMed]
  • Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997 May;30(5):403–418. [PubMed]
  • Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992 Jul;34(7):718–721. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group